DAVIS, RICHARD C. – Trademark Portfolio
Entity Type: 01
DAVIS, RICHARD C. has 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include RHEOFILTER. The portfolio includes 1 registered trademark. Filings span 8 Nice Classification classes, led by Class 42 (Computer & Scientific) and Class 5 (Pharmaceuticals). This trademark owner is based in PENSACOLA, FL.
3439 EDINBOROUGH COURT
PENSACOLA, FL 32514
Showing of trademarks Trademarks
Trademark Classifications
DAVIS, RICHARD C.'s trademark portfolio spans 8 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does DAVIS, RICHARD C. have?
DAVIS, RICHARD C. has 17 U.S. trademarks filed with the USPTO. Of these, 1 registered, 9 abandoned, 7 cancelled.
What trademark classes does DAVIS, RICHARD C. file in?
DAVIS, RICHARD C. files trademarks across 8 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are DAVIS, RICHARD C.'s most well-known trademarks?
DAVIS, RICHARD C.'s registered trademark portfolio includes well-known marks such as RHEOFILTER. These are among 1 currently registered trademark in the portfolio.
What is DAVIS, RICHARD C.'s trademark registration success rate?
DAVIS, RICHARD C. has a 6% trademark registration rate, with 1 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.